Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Business Strategy

Set Alert for Business Strategy

Profile: Boehringer’s Andersen On Volleyball And Leadership Learnings, Storytelling

Boehringer Ingelheim’s Head of Human Pharma Regions, Timmo Rousku Andersen shares with Scrip glimpses of his life and professional journey including distinct parallels between sports and leadership against the backdrop of the wider commercialization efforts for blockbuster therapy Jardiance.

Commercial Business Strategies

Behind A Rekindled Dream And China Biotech’s New Reality

The latest mega deals aimed at bringing Chinese innovation to the US have rekindled go-global hopes for a sector badly needing some cheer. But some investors say out-licensing may be the best route and that Chinese biotech must scale back its do-all mentality and focus on what it does best amid a new reality.

China Deals

Takeda On Continued Lookout For Assets After Recent Deals

Leading Japanese firm reports solid growth in its fiscal nine months as it hints more may be to come after recent major deals to expand the mid- to late-stage pipeline and highlights progress for some key internal assets.

Commercial Business Strategies

Lilly Focuses On ‘Traditional’ Approval For Donanemab, Increased Mounjaro Production

Mounjaro’s fourth quarter sales disappointed some analysts, but the launch remains off to a strong start. Donanemab now on track for full approval in Alzheimer’s, CEO Ricks pledges.

Sales & Earnings Business Strategies

Merck & Co. Remains 'Very Confident' In TIGIT

Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.

Cancer ImmunoOncology

Novartis Excited About Iptacopan But Downcast After Huntington’s Blow

The Swiss major is close to its first submission for ‘pipeline in a pill’ iptacopan but has conceded defeat with branaplam as a potential treatment for Huntington’s disease.

Neurology Clinical Trials

Continuity Or Change? Roche’s New CEO And Pharma Leader Take On Big Strategy Question

Roche will suffer a hangover from its COVID-19 successes this year as revenues stagnate and its future strategy is yet to be laid out by incoming CEO Thomas Schinecker.

Sales & Earnings Strategy

From Science To Commercialization: How Genexine Is Making The Shift

Genexine CEO Neil Warma talks to Scrip in this audio interview about a wide range of topics, including key strategy changes, ambitions to become a leading global biopharma, as well as challenges he has faced since joining the Korean biotech.

South Korea ImmunoOncology

Evelo Forges Ahead In Psoriasis As Atopic Dermatitis Pathway Narrows

The company said the first three cohorts of its Phase II atopic dermatitis study failed, while another trial with a faster-release formulation of EDP1815 continues, along with a Phase III study in psoriasis.

Clinical Trials Dermatology

GSK Exceeded Expectations In 2022, Now Looking For Edge Over Pfizer In RSV Battle

Having outperformed in 2022, GSK is gearing up for key regulatory and market access decisions on its RSV vaccine, but is confident it holds superior data compared with rival Pfizer.

Infectious Diseases Business Strategies

Novartis CEO Laments Europe’s Anti-Innovation Atmosphere

Europe does not have a pricing environment that rewards innovation which improves outcomes for patients, according to Vas Narasimhan, although Germany seems to be the best of a bad bunch.

Sales & Earnings Innovation

Gilead Keeps Focus On HIV, Long-Acting Drugs And Growth Through Oncology

Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.

Strategy Oncology
See All
UsernamePublicRestriction

Register